Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 8/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203800 | 0.89 | FYN (0.53) | PIM1FYNNTRK1IKBKB | |
| SCHEMBL1203203 | 0.85 | PIM1 (0.42) | PIM1FYNMKNK1TGFBR1 | |
| SCHEMBL1202963 | 0.84 | PIM1 (0.43) | PIM1FYNTGFBR1 | |
| SCHEMBL1203100 | 0.81 | PIM1 (0.66) | PIM1FYNNTRK1KDM4ENTRK3 | |
| SCHEMBL1203202 | 0.80 | NTRK1 (0.46) | PIM1FYNNTRK1KDM4ENTRK3 | |
| SCHEMBL1202088 | 0.80 | FYN (0.63) | PIM1FYNNTRK1KDM4ENTRK3 | |
| SCHEMBL1202162 | 0.80 | FYN (0.51) | PIM1FYNNTRK1KDM4ENTRK3 | |
| SCHEMBL2902453 | 0.79 | PIM1 (0.61) | PIM1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL1051257 | 0.77 | PIM1 (1.00) | PIM1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL1202066 | 0.77 | FYN (0.56) | PIM1FYNNTRK1KDM4ENTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | PIM1 1/4885FYN 403/4885NTRK1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.